17,261 trials
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52 — 64.6; 57.4; 69.7; 66.3 Percentage of participants — p=0.8076
Colorectal Adenocarcinoma · Metastatic Microsatellite Stable Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Overall Response Rate (ORR) — 2; 16 Participants
HIV/AIDS · Contraception
Primary: Proportion of Participants That Ovulate During Month 3 — 11; 0 Participants — p=<.001
Presbyopia · Refractive Errors · Eye Diseases
Primary: Percentage of Participants With a ≥ 3-line Improvement in Near Vision and no Loss ≥ 5 Letters Distance Vision — 74.0; 75.5; 4.3 percentage of participants — p=<0.0001
Pathological Gambling · Gambling Disorder
Primary: Yale Brown Obsessive Compulsive Scale Modified for Pathological Gambling (PG-YBOCS) — -11.76; -11.86 units on a scale
Advanced Malignant Solid Neoplasm · Ann Arbor Stage III Non-Hodgkin Lymphoma · Ann Arbor Stage IV Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 0 percentage of patients
Postoperative Delirium · Postoperative Cognitive Dysfunction
Primary: Number of Adverse Events (AEs) of Grade II or Higher Per Patient — 1; 2 events per participant — p=0.025
Chronic Pancreatitis
Primary: Change in Prostaglandin E2 (PGE2) Concentrations — -457.7; -840.4 pg/ml
Erector Spinae Plane Block · Pain Control · Post-Operative Pain, Chronic
Primary: Quantitate the Amount of Opioid Medication Required to Provide Pain Relief-Cumulative First 48 Hours — 80.2; 54.9 Morphine Milligram Equivalents
Chronic Kidney Disease
Primary: Change From Baseline in Log Transformed Urine Albumin Creatinine Ratio (UACR) Measured in 10-hour Urine After 20 Weeks of Trial Treatment — -0.210; -0.190; -0.217; 0.018…
ISS Stage I Plasma Cell Myeloma · ISS Stage II Plasma Cell Myeloma · ISS Stage III Plasma Cell Myeloma
Primary: Number of Participants With Adverse Events — 8 Participants
Glabellar Frown Lines
Primary: Duration of Effect Described by Kaplan-Meier Analysis — 183; 148; 149 Days — p=0.0109
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving a 20% Improvement in American College of Rheumatology (ACR) Criteria at Week 8 — 47; 61; 69; 73 Percentage of participants
Non Small Cell Lung Cancer
Primary: Overall Survival — 19.2 Months
Asthma
Primary: Change From Baseline in PC20 After Each Treatment Period Assessed by Methacholine (MCh) Challenge Test — 3.7; 1.2 mg/mL — p=0.000813